Pathkey.AI wins $25,000 trial review contract
By Jon CuthbertKey points
- Pathkey.AI subsidiary TrialKey signed a contract to evaluate Paradigm’s Phase 3 osteoarthritis trial data.
- The agreement carries a total transaction value of $25,000 plus GST.
- Pathkey stated the agreement converts TrialKey's analytical offering into active commercial project work.
Pathkey.AI (ASX:PKY) announced that its subsidiary TrialKey secured an evaluation services agreement valued at $25,000 plus GST.
The contract follows a September report where Paradigm Biopharmaceuticals stated an interim analysis failed to reach efficacy thresholds.
TrialKey will analyse protocol details, dosing interruptions, and regional differences across global trial sites to identify potential statistical variations.
Following the announcement, the Pathkey share price was unchanged at $0.016.
The company indicated that future priorities include additional biotechnology engagements and pilot licensing for clinical research organisations.
Pathkey.AI continues to expand internal machine-learning models, which combine historical trial datasets to assess clinical study design risks.
